CA2861695C - Method of isolating human antibodies - Google Patents
Method of isolating human antibodies Download PDFInfo
- Publication number
- CA2861695C CA2861695C CA2861695A CA2861695A CA2861695C CA 2861695 C CA2861695 C CA 2861695C CA 2861695 A CA2861695 A CA 2861695A CA 2861695 A CA2861695 A CA 2861695A CA 2861695 C CA2861695 C CA 2861695C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- antibody
- ebv
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 88
- 210000001806 memory b lymphocyte Anatomy 0.000 claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims description 171
- 239000000427 antigen Substances 0.000 claims description 59
- 108091007433 antigens Proteins 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 claims description 45
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 38
- 238000004113 cell culture Methods 0.000 claims description 38
- 230000027455 binding Effects 0.000 claims description 29
- 108010052044 polyclonal B cell activator Proteins 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102100036465 Autoimmune regulator Human genes 0.000 claims description 21
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 claims description 21
- 238000010367 cloning Methods 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 17
- 239000012190 activator Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 238000007865 diluting Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000009257 reactivity Effects 0.000 claims description 6
- 230000003248 secreting effect Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 108700010070 Codon Usage Proteins 0.000 claims description 2
- 108050001049 Extracellular proteins Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 239000002458 cell surface marker Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 38
- 201000010099 disease Diseases 0.000 abstract description 24
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 18
- 208000027866 inflammatory disease Diseases 0.000 abstract description 11
- 230000004913 activation Effects 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 239000006228 supernatant Substances 0.000 description 43
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 29
- 239000002609 medium Substances 0.000 description 26
- 208000035900 Autoimmune polyendocrinopathy type 1 Diseases 0.000 description 24
- 208000011580 syndromic disease Diseases 0.000 description 19
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000002955 isolation Methods 0.000 description 12
- 206010018364 Glomerulonephritis Diseases 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 11
- 208000010668 atopic eczema Diseases 0.000 description 11
- 239000012228 culture supernatant Substances 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000000172 allergic effect Effects 0.000 description 10
- 238000007747 plating Methods 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 9
- 238000010369 molecular cloning Methods 0.000 description 9
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 8
- 239000012979 RPMI medium Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000013691 Interleukin-17 Human genes 0.000 description 7
- 108050003558 Interleukin-17 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 102000004338 Transferrin Human genes 0.000 description 7
- 108090000901 Transferrin Proteins 0.000 description 7
- 206010047115 Vasculitis Diseases 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000012581 transferrin Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000015943 Coeliac disease Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- 206010034277 Pemphigoid Diseases 0.000 description 6
- 210000000628 antibody-producing cell Anatomy 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 102100030703 Interleukin-22 Human genes 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 208000024780 Urticaria Diseases 0.000 description 5
- 206010046851 Uveitis Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 108010074109 interleukin-22 Proteins 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 4
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 4
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 208000003441 Transfusion reaction Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 208000016354 hearing loss disease Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 206010043778 thyroiditis Diseases 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 3
- 208000002691 Choroiditis Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010011715 Cyclitis Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 description 3
- 206010025280 Lymphocytosis Diseases 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 208000031845 Pernicious anaemia Diseases 0.000 description 3
- 206010036105 Polyneuropathy Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 206010039705 Scleritis Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 206010047124 Vasculitis necrotising Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000003278 cryoglobulinemia Diseases 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 230000007824 polyneuropathy Effects 0.000 description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 3
- 208000002574 reactive arthritis Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 208000035939 Alveolitis allergic Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000006373 Bell palsy Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000208199 Buxus sempervirens Species 0.000 description 2
- 208000031976 Channelopathies Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010051392 Diapedesis Diseases 0.000 description 2
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 206010019939 Herpes gestationis Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 206010028665 Myxoedema Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 208000002479 balanitis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 208000024376 chronic urticaria Diseases 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 206010014801 endophthalmitis Diseases 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000037890 multiple organ injury Diseases 0.000 description 2
- 208000003786 myxedema Diseases 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 208000005963 oophoritis Diseases 0.000 description 2
- 201000005737 orchitis Diseases 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
- 108700006471 APECED Proteins 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010062269 Adrenalitis Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 206010001881 Alveolar proteinosis Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003251 Arthritis climacteric Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 206010003487 Aspergilloma Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000025985 Central nervous system inflammatory disease Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010010619 Congenital rubella infection Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000005235 Echovirus Infections Diseases 0.000 description 1
- 206010014190 Eczema asteatotic Diseases 0.000 description 1
- 206010014201 Eczema nummular Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014982 Epidermal and dermal conditions Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015153 Erythema annulare Diseases 0.000 description 1
- 206010055035 Erythema dyschromicum perstans Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 208000030644 Esophageal Motility disease Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 201000005708 Granuloma Annulare Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 206010023335 Keratitis interstitial Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000017119 Labyrinth disease Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 206010024436 Lichen spinulosus Diseases 0.000 description 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 208000026433 Pemphigus erythematosus Diseases 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010036242 Post vaccination syndrome Diseases 0.000 description 1
- 206010036297 Postpartum hypopituitarism Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010036697 Primary hypothyroidism Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000021329 Refractory celiac disease Diseases 0.000 description 1
- 206010038422 Renal cortical necrosis Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- 201000009895 Sheehan syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010042342 Subcorneal pustular dermatosis Diseases 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 206010051446 Transient acantholytic dermatosis Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- 206010070517 Type 2 lepra reaction Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 208000014926 Vesiculobullous Skin disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- 208000037855 acute anterior uveitis Diseases 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010063452 arteriosclerotic retinopathy Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000015440 bird fancier lung Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 208000010353 central nervous system vasculitis Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000008191 cerebritis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000011191 dyskinesia of esophagus Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000009320 ethmoid sinusitis Diseases 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000003485 founder effect Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 201000006916 frontal sinusitis Diseases 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 102000044389 human CD22 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 201000006904 interstitial keratitis Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000005430 kidney cortex necrosis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000029631 linear IgA Dermatosis Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000008836 maxillary sinusitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000028780 ocular motility disease Diseases 0.000 description 1
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 208000029308 periodic paralysis Diseases 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 208000006473 polyradiculopathy Diseases 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000004537 pyelitis Diseases 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000006923 sphenoid sinusitis Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000016367 transient hypogammaglobulinemia of infancy Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161580837P | 2011-12-28 | 2011-12-28 | |
| EP11195952.4 | 2011-12-28 | ||
| EP11195952 | 2011-12-28 | ||
| US61/580,837 | 2011-12-28 | ||
| PCT/EP2013/050026 WO2013098420A1 (en) | 2011-12-28 | 2013-01-02 | Method of isolating human antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2861695A1 CA2861695A1 (en) | 2013-07-04 |
| CA2861695C true CA2861695C (en) | 2021-03-30 |
Family
ID=48696366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2861793A Active CA2861793C (en) | 2011-12-28 | 2013-01-02 | Method of providing monoclonal auto-antibodies with desired specificity |
| CA2861695A Active CA2861695C (en) | 2011-12-28 | 2013-01-02 | Method of isolating human antibodies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2861793A Active CA2861793C (en) | 2011-12-28 | 2013-01-02 | Method of providing monoclonal auto-antibodies with desired specificity |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9957319B2 (OSRAM) |
| EP (3) | EP2797952B1 (OSRAM) |
| JP (1) | JP6242808B2 (OSRAM) |
| AU (3) | AU2013206789B2 (OSRAM) |
| CA (2) | CA2861793C (OSRAM) |
| DK (1) | DK2797951T3 (OSRAM) |
| ES (2) | ES2668104T3 (OSRAM) |
| HU (1) | HUE037186T2 (OSRAM) |
| PL (2) | PL2797952T3 (OSRAM) |
| PT (1) | PT2797951T (OSRAM) |
| SI (1) | SI2797952T1 (OSRAM) |
| WO (2) | WO2013098420A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10131709B2 (en) | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
| EP2626367A1 (en) * | 2012-02-10 | 2013-08-14 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Method for obtaining three-dimensional actin structures and uses thereof |
| US20140199319A1 (en) * | 2012-12-14 | 2014-07-17 | Abbvie, Inc. | Methods for increasing the efficiency of hybridoma generation |
| AU2014286131C1 (en) | 2013-07-03 | 2020-02-13 | Immunoqure Ag | Human anti-IFN-alpha antibodies |
| KR102231685B1 (ko) | 2013-07-03 | 2021-03-26 | 이뮤노큐어 아게 | 인간 항-il-32 항체 |
| WO2015001047A1 (en) | 2013-07-03 | 2015-01-08 | Immunoqure Ag | Method of providing anti-human cytokine antibodies for pharmaceutical use |
| EP2863231A1 (en) * | 2013-10-17 | 2015-04-22 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter |
| AU2015282844A1 (en) * | 2014-07-03 | 2016-12-15 | Immunoqure Ag | Human-derived anti-human IL-20 antibodies and assay for the identification of anti-cytokine antibodies |
| EP3217175B1 (en) * | 2014-11-07 | 2020-12-23 | Fujikura Kasei Co., Ltd. | Arteriosclerosis detection method using deoxyhypusine synthase gene as indicator |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| PL3283110T3 (pl) | 2015-04-15 | 2022-06-27 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r) |
| CN108350071A (zh) * | 2015-08-17 | 2018-07-31 | 德国神经退行性疾病中心 | 结合到抗N-甲基-D-天冬氨酸(NMDA)受体抗体的结合区的抗体或抗体片段或非Ig支架 |
| FR3050535B1 (fr) * | 2016-04-25 | 2020-11-13 | Hospices Civils Lyon | Anticorps anti il17 |
| WO2018017996A1 (en) * | 2016-07-22 | 2018-01-25 | University Of Washington | Identification and production of high affinity igm antibodies and derivatives thereof |
| BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Tesaro, Inc. | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
| CA3049536A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| US11619832B2 (en) | 2018-03-08 | 2023-04-04 | Coopervision International Limited | Identification of contact lens wearers predisposed to contact lens discomfort |
| US11098093B2 (en) | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| CN113329759A (zh) | 2019-01-07 | 2021-08-31 | 沙塔克实验室有限公司 | 用于调节γδT细胞的异二聚体蛋白 |
| WO2021250323A1 (en) * | 2020-06-09 | 2021-12-16 | Helsingin Yliopisto | Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto |
| WO2022192625A1 (en) | 2021-03-11 | 2022-09-15 | IgGenix, Inc. | Methods and systems for predicting allergic response |
| WO2023213400A1 (en) * | 2022-05-05 | 2023-11-09 | Institute For Research In Biomedicine | Antibodies against chemokines, method for identifying said antibodies and uses thereof |
| CN115724983B (zh) * | 2022-10-10 | 2023-09-19 | 宝船生物医药科技(上海)有限公司 | 一种针对抗csf1r单克隆抗体的抗独特型抗体及其应用 |
| WO2025158009A1 (en) | 2024-01-26 | 2025-07-31 | Almirall S.A. | Bispecific molecules and methods of treatment using the same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| DK9091D0 (da) | 1991-01-18 | 1991-01-18 | Novo Nordisk As | Fremgangsmaade til fremstilling af antistoffer |
| DE4130786A1 (de) * | 1991-09-16 | 1993-03-18 | Symbiotec Gmbh | Peptide zur herstellung von mitteln zur diagnose und therapie von systemischen lupus |
| JP2006008694A (ja) * | 1991-09-16 | 2006-01-12 | Symbiotec Ges Zur Forschung & Entwicklung Au F Dem Gebiet Der Biotechnologie Mbh | 全身性エリテマトーデスの診断、治療製剤製造用ペプチド |
| EP1024191B8 (en) | 1991-12-02 | 2008-11-05 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| ATE173016T1 (de) | 1992-08-21 | 1998-11-15 | Biogen Inc | Von tat abgeleitete transportpolypeptide |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0776906A3 (de) * | 1995-10-19 | 1998-02-25 | Imtec Immundiagnostika Gmbh | Peptide des Antigens Sm-D und ihre Verwendung, insbesondere für die Diagnostik des SLE |
| US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| FI973762A0 (fi) | 1997-09-23 | 1997-09-23 | Krohn Kai | Ny gen |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| US7638604B2 (en) * | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| US20030044870A1 (en) | 2001-07-13 | 2003-03-06 | Peter Sehr | Generic capture elisa using recombinant fusion proteins for detecting antibodies in biological samples |
| EP1511772B1 (en) | 2002-05-28 | 2011-11-23 | Omrix Biopharmaceuticals Inc. | Method for obtaining anti-idiotype antibodies |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US7158410B2 (en) | 2004-08-27 | 2007-01-02 | Micron Technology, Inc. | Integrated DRAM-NVRAM multi-level memory |
| EP1974020B1 (en) | 2005-12-16 | 2011-06-15 | Ribovax Biotechnologies SA | Methods for obtaining immortalized antibody secreting cells |
| EP2377887A1 (en) * | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| JP4059404B2 (ja) * | 2006-09-22 | 2008-03-12 | 栄研化学株式会社 | 甲状腺機能を刺激する活性を持つ抗体 |
| SI2436696T1 (sl) * | 2007-01-05 | 2017-10-30 | University Of Zurich | Anti-beta-amiloidno protitelo in načini njegove uporabe |
| MX2009009926A (es) | 2007-03-13 | 2010-03-15 | Univ Zuerich | Anticuerpo tumor-especifico humano monoclonal. |
| MX2010004482A (es) * | 2007-10-25 | 2010-07-06 | Trellis Bioscience Inc | Anticuerpos anti-proteina g vsr. |
| GB0807413D0 (en) * | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| AU2009245440C1 (en) * | 2008-05-05 | 2013-03-14 | Novimmune Sa | Anti-IL-17A/IL-17F cross-reactive antibodies and methods of use thereof |
| EP2307453A1 (en) | 2008-06-16 | 2011-04-13 | University Of Zurich | Method of providing immunoglobulin secreting b lymphocytes and human antibodies |
| EA030826B1 (ru) | 2008-12-19 | 2018-10-31 | Панима Фармасьютикалз Аг | ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА |
| AU2010244142B2 (en) * | 2009-05-05 | 2016-07-21 | Novimmune Sa | Anti-IL-17F antibodies and methods of use thereof |
| EP2258727A1 (en) | 2009-05-27 | 2010-12-08 | Wezen Biopharmaceuticals S.r.l. A Socio Unico | Immunoglobulin preparation for the treatment of autoimmune diseases and immune system disorders |
-
2013
- 2013-01-02 SI SI201331457T patent/SI2797952T1/sl unknown
- 2013-01-02 ES ES13700002.2T patent/ES2668104T3/es active Active
- 2013-01-02 PL PL13700013T patent/PL2797952T3/pl unknown
- 2013-01-02 WO PCT/EP2013/050026 patent/WO2013098420A1/en not_active Ceased
- 2013-01-02 DK DK13700002.2T patent/DK2797951T3/en active
- 2013-01-02 PL PL13700002T patent/PL2797951T3/pl unknown
- 2013-01-02 US US14/368,749 patent/US9957319B2/en active Active
- 2013-01-02 CA CA2861793A patent/CA2861793C/en active Active
- 2013-01-02 HU HUE13700002A patent/HUE037186T2/hu unknown
- 2013-01-02 EP EP13700013.9A patent/EP2797952B1/en active Active
- 2013-01-02 JP JP2014549503A patent/JP6242808B2/ja not_active Expired - Fee Related
- 2013-01-02 EP EP19159201.3A patent/EP3546481B1/en active Active
- 2013-01-02 CA CA2861695A patent/CA2861695C/en active Active
- 2013-01-02 AU AU2013206789A patent/AU2013206789B2/en not_active Ceased
- 2013-01-02 PT PT137000022T patent/PT2797951T/pt unknown
- 2013-01-02 ES ES19159201T patent/ES2964168T3/es active Active
- 2013-01-02 US US14/369,467 patent/US9475872B2/en not_active Expired - Fee Related
- 2013-01-02 AU AU2013206788A patent/AU2013206788B2/en not_active Ceased
- 2013-01-02 EP EP13700002.2A patent/EP2797951B1/en active Active
- 2013-01-02 WO PCT/EP2013/050024 patent/WO2013098419A1/en not_active Ceased
-
2017
- 2017-06-29 AU AU2017204449A patent/AU2017204449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013098420A1 (en) | 2013-07-04 |
| PL2797951T3 (pl) | 2018-07-31 |
| EP2797952A1 (en) | 2014-11-05 |
| HUE037186T2 (hu) | 2018-08-28 |
| EP2797952B1 (en) | 2019-02-27 |
| EP3546481B1 (en) | 2023-11-08 |
| WO2013098419A1 (en) | 2013-07-04 |
| US20140335098A1 (en) | 2014-11-13 |
| AU2017204449A1 (en) | 2017-07-20 |
| CA2861793A1 (en) | 2013-07-04 |
| DK2797951T3 (en) | 2018-03-12 |
| AU2013206789B2 (en) | 2017-04-13 |
| EP2797951B1 (en) | 2018-01-31 |
| JP6242808B2 (ja) | 2017-12-06 |
| US20140363422A1 (en) | 2014-12-11 |
| CA2861695A1 (en) | 2013-07-04 |
| AU2013206789A1 (en) | 2014-07-17 |
| EP3546481C0 (en) | 2023-11-08 |
| JP2015505244A (ja) | 2015-02-19 |
| EP2797951A1 (en) | 2014-11-05 |
| EP3546481A3 (en) | 2020-01-08 |
| PL2797952T3 (pl) | 2019-09-30 |
| AU2013206788B2 (en) | 2017-11-30 |
| ES2668104T3 (es) | 2018-05-16 |
| US9475872B2 (en) | 2016-10-25 |
| ES2964168T3 (es) | 2024-04-04 |
| US9957319B2 (en) | 2018-05-01 |
| CA2861793C (en) | 2023-08-01 |
| AU2013206788A1 (en) | 2014-07-10 |
| SI2797952T1 (sl) | 2019-07-31 |
| PT2797951T (pt) | 2018-03-23 |
| EP3546481A2 (en) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2861695C (en) | Method of isolating human antibodies | |
| US10570208B2 (en) | Antagonistic anti-OX40L antibodies and methods of their use | |
| AU2007213716B2 (en) | Antigenic GM-CSF peptides and antibodies to GM-CSF | |
| US20140314744A1 (en) | Mcam antagonists and methods of treatment | |
| WO2013052772A2 (en) | Anti-human sema4a antibodies useful to treat disease | |
| WO2018178007A1 (en) | Methods and pharmaceutical compositions for inhibiting t cell proliferation in a subject in need thereof | |
| AU2013201228A1 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
| EP2632492B1 (en) | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS | |
| CA2957314C (en) | Antagonistic anti-ox40l antibodies and methods of their use | |
| HK40039084A (en) | Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171018 |